Records containing: Multiple Sclerosis, Secondary Progressive

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2020-10-19
  The Safety and Cost-effectiveness of Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS): a Randomized Rater-blinded Multicenter Trial.
• CLINICAL_TRIALS study record update · 2020-07-28
  A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis
• CLINICAL_TRIALS study record update · 2020-04-08
  A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis
• CLINICAL_TRIALS study record update · 2020-02-24
  Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)
• CLINICAL_TRIALS study record update · 2018-02-12
  A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals With MS
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2017-03-27
  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis
• CLINICAL_TRIALS study record update · 2017-01-11
  An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
• CLINICAL_TRIALS study record update · 2014-10-27
  Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis
• CLINICAL_TRIALS study record update · 2013-11-04
  Neuropsychological Assessments in the Multiple Sclerosis Clinic
• CLINICAL_TRIALS study record update · 2009-08-13
  A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis